title: Is public meningococcal C vaccination the preferred value for money at cost-neutral?
authors.affiliation: Te Arai BioFarma Ltd, Herne Bay, Auckland, New Zealand.
authors.forename: Lance
authors.initials: L
authors.lastname: Gravatt
mesh_terms: D003362:Cost-Benefit Analysis; D006801:Humans; D032541:Mass Vaccination / Q000191:economics*; D008589:Meningococcal Infections / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000191:economics*; D038542:Neisseria meningitidis, Serogroup C; D009520:New Zealand; D019057:Quality-Adjusted Life Years
chemical_list: D022401:Meningococcal Vaccines; C410218:serogroup C meningococcal conjugate vaccine